Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

Abdulrahman E Koshak, Emad A Koshak, Abdullah F Mobeireek, Mazen A Badawi, Siraj O Wali, Husam M Malibary, Ali F Atwah, Meshari M Alhamdan, Reem A Almalki, Tariq A Madani, Abdulrahman E Koshak, Emad A Koshak, Abdullah F Mobeireek, Mazen A Badawi, Siraj O Wali, Husam M Malibary, Ali F Atwah, Meshari M Alhamdan, Reem A Almalki, Tariq A Madani

Abstract

Background: Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recommended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19.

Methods: All adult patients with mild COVID-19 symptoms presented to King Abdulaziz University Hospital, Jeddah, Saudi Arabia, were recruited for an open label randomized clinical trial (RCT). They were randomly divided into control or treatment groups, with the latter receiving 500 mg NSO (MARNYS® Cuminmar) twice daily for 10 days. Symptoms were daily monitored via telecommunication. The primary outcome focused on the percentage of patients who recovered (symptom-free for 3 days) within 14-days. The trial was registered at clinicaltrials.gov (NCT04401202).

Results: A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53 % of patients were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered patients in NSO group (54[62 %]) was significantly higher than that in the control group (31[36 %]; p = 0.001). The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the control group (12.3 ± 2.8 days); p = 0.001.

Conclusions: NSO supplementation was associated with faster recovery of symptoms than usual care alone for patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with placebo-controlled, double-blinded studies.

Keywords: COVID-19; Herbal medicine; Nigella sativa; SARS-CoV-2.

Conflict of interest statement

The authors report no declarations of interest.

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Flow diagram of patient’s enrollment.
Fig. 2
Fig. 2
The number of patients who recovered within the study period.

References

    1. World Health Organization . 2020. Timeline of WHO’s response to COVID-19. Published 2020. (Accessed 6 August 2020)
    1. Saudi Center for Disease Prevention and Control . 2020. Daily updates.
    1. Vijayvargiya P., Esquer Garrigos Z., Castillo Almeida N.E., Gurram P.R., Stevens R.W., Razonable R.R. Treatment considerations for COVID-19: a critical review of the evidence (or lack thereof) Mayo Clin Proc. 2020;95(7):1454–1466. doi: 10.1016/j.mayocp.2020.04.027.
    1. World Health Organization . 2020. Clinical management of COVID-19. Published 2020. (Accessed 27 August 2020)
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648.
    1. Suleyman G., Fadel R.A., Malette K.M. Clinical Characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan detroit. JAMA Netw Open. 2020;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270.
    1. Richardson S., Hirsch J.S., Narasimhan M. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA - J Am Med Assoc. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775.
    1. Lin L.T., Hsu W.C., Lin C.C. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014;4(1):24–35. doi: 10.4103/2225-4110.124335.
    1. Silveira D., Prieto-Garcia J.M., Boylan F. COVID-19: is there evidence for the use of herbal medicines as adjuvant symptomatic therapy? Front Pharmacol. 2020;11:1479. doi: 10.3389/fphar.2020.581840.
    1. Shirvani H., Rostamkhani F., Arabzadeh E., Mohammadi F., Mohammadi F. Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: a contemporary review. Sport Sci Health. 2021;(May) doi: 10.1007/s11332-021-00787-y.
    1. Khazdair M.R., Ghafari S., Sadeghi M. Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19. Pharm Biol. 2021;59(1):696–703. doi: 10.1080/13880209.2021.1931353.
    1. Ahmad A., Husain A., Mujeeb M. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–352. doi: 10.1016/S2221-1691(13)60075-1.
    1. Koshak A., Wei L., Koshak E. Nigella sativa supplementation improves asthma control and biomarkers: a randomized, double-blind, placebo-controlled trial. Phyther Res. 2017;(January) doi: 10.1002/ptr.5761.
    1. Razmpoosh E., Safi S., Abdollahi N. The effect of Nigella sativa on the measures of liver and kidney parameters: a systematic review and meta-analysis of randomized-controlled trials. Pharmacol Res. 2020;156:104767. doi: 10.1016/j.phrs.2020.104767.
    1. Molla S., Abul M., Azad K. A review on antiviral effects of Nigella Sativa L. Pharmacologyonline. 2019;2:47–53. (Accessed 18 March 2020)
    1. Barakat A.B., Shoman S.A., Dina N., Alfarouk O.R. Antiviral activity and mode of action of Dianthus caryophyllus L. and Lupinus termes L. seed extracts against in vitro herpes simplex and hepatitis A viruses infection. J Microbiol Antimicrob. 2010;2(3):23–29.
    1. Ulasli M., Gurses S.A., Bayraktar R. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep. 2014;41(3):1703–1711. doi: 10.1007/s11033-014-3019-7.
    1. Dorra N., El-Berrawy M., Sallam S., Mahmoud R. Evaluation of antiviral and antioxidant activity of selected herbal extracts. J High Inst Public Heal. 2019;49(1):36–40. doi: 10.21608/jhiph.2019.29464.
    1. Oyero O.G., Toyama M., Mitsuhiro N. Selective inhibition of hepatitis c virus replication by alpha-zam, a nigella sativa seed formulation. Afr J Tradit Complement Altern Med. 2016;13(6):144–148. doi: 10.21010/ajtcam.v13i6.20.
    1. Salem M.L., Hossain M.S. Protective effect of black seed oil from Nigella sativa against murine cytomegalovirus infection. Int J Immunopharmacol. 2000;22(9):729–740. doi: 10.1016/S0192-0561(00)00036-9.
    1. Onifade A.A., Jewell A.P., Adedeji W.A. Nigella sativa concoction induced sustained seroreversion in HIV patient. Afr J Tradit Complement Altern Med. 2013;10(5):332–335.
    1. Onifade A.A., Jewell A.P., Ajadi T.A., Rahamon S.K., Ogunrin O.O. Effectiveness of a herbal remedy in six HIV patients in Nigeria. J Herb Med. 2013;3(3):99–103. doi: 10.1016/j.hermed.2013.04.006.
    1. Barakat E.M.F., El Wakeel L.M., Hagag R.S. Effects of Nigella sativa on outcome of hepatitis C in Egypt. World J Gastroenterol. 2013;19(16):2529–2536. doi: 10.3748/wjg.v19.i16.2529.
    1. Koshak A.E., Koshak E.A. Nigella sativa L as a potential phytotherapy for coronavirus disease 2019: a mini review of in silico studies. Curr Ther Res - Clin Exp. 2020;93:100602. doi: 10.1016/j.curtheres.2020.100602.
    1. Sultan M.T., Buttxs M.S., Qayyum M.M.N., Suleria H.A.R. Immunity: plants as effective mediators. Crit Rev Food Sci Nutr. 2014;54(10):1298–1308. doi: 10.1080/10408398.2011.633249.
    1. Mady W.H., Arafa A., Hussein A.S., Aly M.M., Madbouly H.M. Nigella sativa oil as an immunostimulant adjuvant in H5 based DNA vaccine of H5N1 avian influenza virus. Glob Vet. 2013;10(6):663–668. doi: 10.5829/idosi.gv.2013.10.6.73101.
    1. Haq A., Abdullatif M., Lobo P.I., Khabar K.S.A., Sheth K.V., Al-Sedairy S.T. Nigella sativa: effect on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. Immunopharmacology. 1995;30(2):147–155. doi: 10.1016/0162-3109(95)00016-M.
    1. Gholamnezhad Z., Boskabady M.H., Hosseini M. Effect of Nigella sativa on immune response in treadmill exercised rat. BMC Complement Altern Med. 2014;14:437. doi: 10.1186/1472-6882-14-437.
    1. Majdalawieh A.F., Fayyad M.W. Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: a comprehensive review. Int Immunopharmacol. 2015;28(1):295–304. doi: 10.1016/j.intimp.2015.06.023.
    1. Koshak A., Fiebich B., Koshak E., Heinrich M. Comparative anti-inflammatory/immunomodulatory effect of different extracts of medicinal plant Nigella sativa. European Academy of Allergy and Clinical Immunology Congress; Barcelona, Spain; 2015. EAACI Online Library . (Accessed 6 March 2017)
    1. Al-Ghamdi M.S. The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J Ethnopharmacol. 2001;76(1):45–48. doi: 10.1016/S0378-8741(01)00216-1.
    1. Gilani A.H., Aziz N., Khurram I.M., Chaudhary K.S., Iqbal A. Bronchodilator, spasmolytic and calcium antagonist activities of Nigella sativa seeds (Kalonji): a traditional herbal product with multiple medicinal uses. J Pak Med Assoc. 2001;51(3):115–120. (Accessed 11 September 2016)
    1. Boskabady M.H., Keyhanmanesh R., Khamneh S., Ebrahimi M.A. The effect of Nigella sativa extract on tracheal responsiveness and lung inflammation in ovalbumin-sensitized guinea pigs. Clinics. 2011;66(5):879–887. doi: 10.1590/S1807-59322011000500027.
    1. Babaei F., Mirzababaei M., Nassiri-Asl M., Hosseinzadeh H. Review of registered clinical trials for the treatment of COVID-19. Drug Dev Res. 2021;82(4):474–493. doi: 10.1002/ddr.21762.
    1. Medscape Drugs & Diseases . 2020. What are complications of patients with coronavirus disease 2019 (COVID-19)? Published 2020. (Accessed 27 June 2021)
    1. International Severe Acute Respiratory and Emerging Infections Consortium . 2020. ISARIC COVID-19 report: 08 June 2020.
    1. Whitcroft K.L., Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA - J Am Med Assoc. 2020;323(24):2512–2514. doi: 10.1001/jama.2020.8391.
    1. U.S. Food and Drug Administration Coronavirus (COVID-19) update: FDA reiterates importance of close patient supervision for “off-label” use of antimalarial drugs to mitigate known risks, including heart rhythm problems. FDA-COVID-19-update.
    1. U.S. Food and Drug Administration . 2020. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. FDA-COVID-19-update. Published 2020. (Accessed 24 September 2020)
    1. Skipper C.P., Pastick K.A., Engen N.W. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623–631. doi: 10.7326/M20-4207.
    1. Mitjà O., Corbacho-Monné M., Ubals M. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1009.
    1. Sahebnasagh A., Avan R., Saghafi F. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020;1:3. doi: 10.1007/s43440-020-00152-9.
    1. El Sayed S.M., Aboonq M.S., El Rashedy A.G. Promising preventive and therapeutic effects of TaibUVID nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (a retrospective study) Am J Blood Res. 2020;10(5):266–282. (Accessed 27 June 2021)
    1. Ashraf S., Ashraf S., Ashraf M. Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): a multi-center placebo-controlled randomized clinical trial. medRxiv. 2020;2020(January) doi: 10.1101/2020.10.30.20217364. 10.30.20217364.
    1. Sun X., Wang T., Cai D. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42. doi: 10.1016/j.cytogfr.2020.04.002.
    1. Wang J., Jiang M., Chen X., Montaner L.J. Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17–41. doi: 10.1002/JLB.3COVR0520-272R.
    1. Islam M.N., Hossain K.S., Sarker P.P. Revisiting pharmacological potentials of Nigella sativa seed: a promising option for COVID-19 prevention and cure. Phyther Res. 2020;(October):1–16. doi: 10.31219/.
    1. Kulyar M.Fe.A., Li R., Mehmood K., Waqas M., Li K., Li J. Potential influence of Nagella sativa (Black cumin) in reinforcing immune system: a hope to decelerate the COVID-19 pandemic. Phytomedicine. 2020;(July):153277. doi: 10.1016/j.phymed.2020.153277.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner